Status:
COMPLETED
ST-segment Elevation as an AF Endophenotype
Lead Sponsor:
Vanderbilt University Medical Center
Collaborating Sponsors:
National Heart, Lung, and Blood Institute (NHLBI)
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to look for a similarity in people's genes that may help understand which people could benefit from certain drugs for the treatment of atrial fibrillation (AF).
Detailed Description
Current drug therapies to suppress AF are incompletely and unpredictably effective and carry significant (albeit generally small) risks of serious adverse effects, including drug-induced long QT syndr...
Eligibility Criteria
Inclusion
- 18 years of age or older
- Undergoing AF ablation at Vanderbilt or MGH
Exclusion
- Patients taking membrane active anti-arrhythmic drugs with sodium channel blocking properties (amiodarone, dronedarone, flecainide, propafenone) at the time of the ablation
- Patients with a history of Brugada syndrome or type 1 Brugada ECG pattern on the baseline ECG
- Patients with a history of drug-induced torsades de pointes
- Patients with a known history of hypersensitivity to procainamide, procaine or related drugs
- Patients with a history of systemic lupus erythematosus and myasthenia gravis
- Patients with a history of second degree AV block (Mobitz type II) or third degree AV block
- Women of child-bearing potential unless post-menopausal, surgically sterile, or have a negative pregnancy test day on the day of procedure
- Patients with dual chamber pacemakers or implantable defibrillators requiring ventricular pacing (uninterpretable ECG)
- Patients unable to give informed consent
Key Trial Info
Start Date :
November 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2015
Estimated Enrollment :
161 Patients enrolled
Trial Details
Trial ID
NCT01205529
Start Date
November 1 2010
End Date
June 1 2015
Last Update
May 2 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232